Literature DB >> 2571943

Kinetic properties of the in vivo accumulation of 3H-(-)-N-n-propylnorapomorphine in mouse brain.

S B Ross1, D M Jackson.   

Abstract

(1) The influence of various dopamine (DA) receptor agonists and antagonists on the kinetic properties of the specific binding of 3H(-)-N-n-propylnorapomorphine (NPA) in the mouse striatum in vivo was studied. The specific binding of 3H-NPA, defined as the difference between the radioactivity in the striatum and cerebellum, was completely antagonized by the selective D-2 receptor antagonist raclopride but not by the selective D-1 antagonist SCH 23390, showing that the binding occurs exclusively to the D-2 receptors. (2) The selective D-2 receptor agonists pergolide and quinpirole inhibited the 3H-NPA binding biphasically at low doses, indicating that these DA receptor agonists have high affinities for a subfraction (10 to 30%) of the NPA binding sites. (3) Increasing the synaptic DA concentration by DA release [(+)-amphetamine] or uptake blockade (amfonelic acid and methylphenidate) inhibited the 3H-NPA binding in a competitive manner (unchanged Bmax, increased KD). Depletion of the DA in the synapses by gamma-butyrolactone or reserpine decreased the apparent KD value. (4) The possibility of estimating changes in the synaptic DA concentration from changes in the apparent KD is discussed. According to the results obtained, the normal concentration of DA in the synaptic cleft in mouse striatum in vivo is about 40 nmol/l and this concentration is increased 2 to 3 times by (+)-amphetamine and amfonelic acid in doses which evoke hyperactivity and stereotypic behaviour.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2571943     DOI: 10.1007/BF00169200

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  29 in total

1.  Absence of receptor reserve at striatal dopamine receptors regulating cholinergic neuronal activity.

Authors:  E Meller; A Enz; M Goldstein
Journal:  Eur J Pharmacol       Date:  1988-10-11       Impact factor: 4.432

2.  Dopamine D2 agonist-induced behavioural depression is reversed by dopamine D1 agonists.

Authors:  D M Jackson; S B Ross; S R Edwards
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

3.  Selective labelling of different dopamine receptors by a new agonist 3H-ligand: 3H-N-propylnorapomorphine.

Authors:  M Titeler; P Seeman
Journal:  Eur J Pharmacol       Date:  1979-06-15       Impact factor: 4.432

4.  3H-N-n-propylnorapomorphine: a novel agonist ligand for central dopamine receptors.

Authors:  I Creese; L Padgett; E Fazzini; F Lopez
Journal:  Eur J Pharmacol       Date:  1979-07-01       Impact factor: 4.432

5.  In vivo binding of N-n-propylnorapomorphine in the rat striatum: quantification after lesions produced by kainate, 6-hydroxydopamine and decortication.

Authors:  J F Van der Werf; J B Sebens; J Korf
Journal:  Eur J Pharmacol       Date:  1984-07-13       Impact factor: 4.432

6.  Relationship between receptor occupancy and response at striatal dopamine autoreceptors.

Authors:  E Meller; K Bohmaker; Y Namba; A J Friedhoff; M Goldstein
Journal:  Mol Pharmacol       Date:  1987-06       Impact factor: 4.436

7.  Dopamine D2 receptor binding sites for agonists. A tetrahedral model.

Authors:  P Seeman; M Watanabe; D Grigoriadis; J L Tedesco; S R George; U Svensson; J L Nilsson; J L Neumeyer
Journal:  Mol Pharmacol       Date:  1985-11       Impact factor: 4.436

8.  Detecting behaviorally relevant changes in extracellular dopamine with microdialysis.

Authors:  W H Church; J B Justice; D B Neill
Journal:  Brain Res       Date:  1987-06-02       Impact factor: 3.252

9.  Comparison of the dopaminergic effects of apomorphine and (-)-N-n-propylnorapomorphine.

Authors:  M K Menon; W G Clark; J L Neumeyer
Journal:  Eur J Pharmacol       Date:  1978-11-01       Impact factor: 4.432

10.  The benzazepine, SCH 23390, inhibits 3H-NPA binding in mouse brain in vivo.

Authors:  P H Andersen; E B Nielsen
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1986-10
View more
  8 in total

1.  Synthesis and Evaluation of Fluorinated Aporphines: Potential Positron Emission Tomography Ligands for D2 Receptors

Authors:  Anna W Sromek; Yu-Gui Si; Tangzhi Zhang; Susan R George; Philip Seeman; John L Neumeyer
Journal:  ACS Med Chem Lett       Date:  2011-03-10       Impact factor: 4.345

2.  Behavioural, biochemical and electrophysiological studies on the motor depressant and stimulant effects of bromocriptine.

Authors:  D M Jackson; L P Martin; L G Larsson; R F Cox; B L Waszczak; S B Ross
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-09       Impact factor: 3.000

3.  Kinetic brain analysis and whole-body imaging in monkey of [11C]MNPA: a dopamine agonist radioligand.

Authors:  Nicholas Seneca; Mette Skinbjerg; Sami S Zoghbi; Jeih-San Liow; Robert L Gladding; Jinsoo Hong; Pavitra Kannan; Edward Tuan; David R Sibley; Christer Halldin; Victor W Pike; Robert B Innis
Journal:  Synapse       Date:  2008-09       Impact factor: 2.562

Review 4.  The dopaminergic basis of human behaviors: A review of molecular imaging studies.

Authors:  Alice Egerton; Mitul A Mehta; Andrew J Montgomery; Julia M Lappin; Oliver D Howes; Suzanne J Reeves; Vincent J Cunningham; Paul M Grasby
Journal:  Neurosci Biobehav Rev       Date:  2009-05-27       Impact factor: 8.989

5.  Occupancy of dopamine D2/3 receptors in rat brain by endogenous dopamine measured with the agonist positron emission tomography radioligand [11C]MNPA.

Authors:  Nicholas Seneca; Sami S Zoghbi; Mette Skinbjerg; Jeih-San Liow; Jinsoo Hong; David R Sibley; Victor W Pike; Christer Halldin; Robert B Innis
Journal:  Synapse       Date:  2008-10       Impact factor: 2.562

6.  Kinetic properties of the accumulation of 3H-raclopride in the mouse brain in vivo.

Authors:  S B Ross; D M Jackson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-07       Impact factor: 3.000

7.  Dopamine in the history of the schizophrenic brain: recent contributions of brain-imaging studies.

Authors:  M Lamelle; A Abi-Dargham
Journal:  Dialogues Clin Neurosci       Date:  2000-12       Impact factor: 5.986

8.  Dopamine Synthesis Capacity is Associated with D2/3 Receptor Binding but Not Dopamine Release.

Authors:  Anne S Berry; Vyoma D Shah; Daniella J Furman; Robert L White; Suzanne L Baker; James P O'Neil; Mustafa Janabi; Mark D'Esposito; William J Jagust
Journal:  Neuropsychopharmacology       Date:  2017-08-17       Impact factor: 7.853

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.